News

The facility will be completely operational by the third quarter of 2013. The company’s South San Francisco facility will continue to carry out its operations to serve existing

Phase II trial being conducted by Novartis will assess INC280 as monotherapy in patients with advanced hepatocellular carcinoma. Under the terms of the deal signed between the companies,

Phase I trial is designed to assess bavituximab as combination therapy along with the chemotherapeutic agent paclitaxel in metastatic HER2-negative breast cancer patients. Bavituximab previously established tumor response

Through the deal, NutraGenesis gains exclusive rights to market Plandai’s patented Phytofare extracts in North America. Plandai marketing sales vice-president and global director Callum Baylis-Duffield said, "This is

The termination is attributed to delay in the expected regulatory approval and launch dates in countries where GSK holds commercialization rights. According to the terms of the deal

According to the deal, Merck, through a subsidiary, and Pfizer will work on the development and marketing of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin)

The most recent lawsuit alleges that the plaintiffs developed urinary and bladder issues, including bladder cancer, after they had consumed Actos and the drug is sold under the

As per the agreement, the Buyer, Bruce Perlowin, will purchase $50,000 of the protein each month for the duration of two years to total $1.2m for the company.

FDA warned that Potiga may cause bluish skin predominantly around lips, fingers and toes and pigment changes in the retina, which may lead to loss of vision. GlaxoSmithKline